Precision Medicine in Cardiovascular Disease

We are at an unusual moment in cardiovascular medicine. For the first time, the biological mechanisms underlying inherited cardiomyopathies and arrhythmia syndromes are not merely characterised but therapeutically addressable. Artificial intelligence is unlocking diagnostic information embedded in data that clinicians have collected for decades but never had the tools to fully read. And a new generation of molecular therapies — myosin inhibitors, RNA silencers, gene editing — is reaching patients with conditions that, until recently, had almost no disease-modifying options. This is genuinely exciting, and it deserves to be said plainly.

It also deserves the kind of analysis that excitement sometimes discourages. Not all precision strategies are equally well-founded. The biological architecture of common cardiovascular disease differs fundamentally from the oncological paradigm that shaped the field’s vocabulary. AI performance in controlled research settings does not always survive contact with real-world clinical environments. And the evidentiary standards for demonstrating that finer stratification produces better outcomes are higher — and more important — than the research community has always acknowledged.

Cardiovascular Medicine – A Field in Transition

The conditions that make cardiovascular precision medicine feasible today did not exist twenty years ago. Whole-exome and whole-genome sequencing have moved from research tools costing millions to clinical instruments costing hundreds. Functional characterisation of genetic variants is advancing rapidly, with variant databases now large enough to support meaningful genotype-phenotype correlation in rare cardiac diseases. AI algorithms trained on millions of ECGs and echocardiograms are detecting patterns invisible to the human eye. And crucially, the therapeutic toolkit has expanded: where inherited cardiomyopathies and amyloidosis once had symptomatic management at best, they now have — or are acquiring — disease-modifying interventions that change the natural history of the condition. The convergence of these developments is creating genuine clinical opportunity. The question worth asking carefully is not whether precision cardiology is real — it is — but where within the cardiovascular landscape it is ready to deliver now, where it is building toward delivery, and where the enthusiasm is running ahead of the evidence in ways that risk misallocating resources and credibility.

Learning from Oncology – Without Being Captured by It

The intellectual framework for precision medicine was forged in oncology, and its achievements there are genuine. Imatinib for BCR-ABL-positive CML, trastuzumab for HER2-positive breast cancer, EGFR inhibitors for correspondingly mutated lung adenocarcinoma: these share a common architecture — a dominant molecular driver, a targeted intervention, and outcomes dramatic enough to dissolve equipoise rapidly. The paradigm works because a single genetic lesion dominates the disease trajectory and a single therapeutic can address it.

Cardiovascular medicine has its own versions of this story, and they are in the rare inherited diseases. Cardiac myosin inhibitors in HCM, TTR-targeting therapies in amyloidosis, genotype-guided management in channelopathies — these represent genuine precision success cases where the oncological analogy holds. The important nuance is that common cardiovascular diseases — coronary artery disease, heart failure, atrial fibrillation, hypertension — have a fundamentally different genetic architecture, and the precision strategies that work in rare disease do not transfer automatically.

The Architecture of Common Cardiovascular Disease

Common cardiovascular diseases emerge from the interaction of hundreds or thousands of genetic variants with decades of environmental exposure. Genome-wide association studies have mapped this landscape with extraordinary resolution: a polygenic risk score for coronary artery disease may aggregate signals across over a million variants, with individual odds ratios typically below 1.10. No single molecular switch dominates. And unlike oncological driver mutations, the genetic contribution to common cardiovascular risk is substantially modifiable by behaviour and pharmacotherapy — the INTERHEART study demonstrated that nine factors account for over 90% of the population-attributable risk for myocardial infarction, consistently across regions and ethnicities.

The distinction matters for research strategy. In common cardiovascular disease, we are not asking which molecular driver determines treatment — we are asking whether finer genetic stratification identifies subgroups in whom effects differ enough to justify the cost and complexity of stratification. That is a harder question, and answering it requires prospective clinical utility data that are still being generated. The absence of that data today is not a reason for pessimism — it is the specification of what the next phase of research needs to produce.

The table below makes the structural contrast explicit. The final row is the most important: the paradigm cases for cardiovascular precision medicine are the rare monogenic conditions, not the common diseases. Understanding this is not a counsel of limitation — it is a map of where the field is strongest now, and where the work of the coming decade needs to happen.